granted a license from China Food and Drug Administration (CFDA) during the beginning of 2018 as the Company had to redesign and adjust product packaging according to the granted license as well as change
Consolidated financial statements Change Increase/(Decrease) For Three Months Period Ended 30 September 2017 2018 THB mm % THB mm % THB mm % Sale Revenue Revenue from selling product under Company’s trademark 1
–2021 Balance by Quarter Change Q2–21 Q1–21 Q2–20 Q2–21 VS Q1–21 Q2–21 VS Q2–20 (Million Baht: MB) (MB) % (MB) % Total revenue 2,081.2 1,824.2 1,187.6 257.0 14.1 893.6 75.2 Total operating expenses
nor significantly different from the average values of the land assessed by an independent appraiser approved by the SEC. An appraiser is Ultima Appraisal Company Limited, who made an assessment on 3
) Criteria for Valuation of Transaction The company offered for sale by the price neither lower than nor significantly different from the average values of the land assessed by an independent appraiser
the market price by the estimated price as at December 31, 2015 amount of 263 million baht as well as using the assessed value of the Department of Land as at December 19, 2017 amount of Baht
meters of buildings, 60 beds hospital, located in San Sai district, Chiang Mai Province and expected to open in 2021. With the value of land and buildings Assessed by the valuation method in the amount of
Province and expected to open in 2021. With the value of land and buildings Assessed by the valuation method in the amount of 762,160,000 baht (according to the appraisal report of Sasirachada Company
production of OEMs of 450-500 million INR. The Company has assessed and analyzed the possibility of the additional investment with a return on investment (IRR) of no less than 17.57%, Net Present Value (NPV
San Sai district, Chiang Mai Province and expected to open in 2021. With the value of land and buildings Assessed by the valuation method in the amount of 762,160,000 baht (according to the appraisal